SOCIAL IMPLICATIONS OF GENETIC PRENATAL SCREENING IN PREGNANCY.

Slides:



Advertisements
Similar presentations
PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Advertisements

© 2009 NHS National Genetics Education and Development CentreGenetics and Genomics for Healthcare This PowerPoint file contains.
Examples of Sound Screening:
Antenatal Screening Dr Emma Parry CMFM
Screening “the systematic application of a test procedure to identify individuals at sufficient risk to warrant diagnostic investigations” CVS 12wks Amniocentesis.
Antenatal Screening Mehreen Yousaf GP STS.
Towards Early Biochemical Screening for Fetal Aneuploidy in the First Trimester Niels Tørring 1, Olav B Petersen 2 1. Department of Clinical Biochemistry,
PSI 2014 Conference The Tower Hotel, Tower Bridge, London Risk Calculation in Screening with Biomarkers Nick Cowans Statistical Programmer Veramed Limited.
Genetics and Primary Care
The New Prenatal Screening Tests
Processes of Technology Diffusion and Implementation Around Prenatal Screening in Europe Jane Sandall, King’s College, London IHT at the HTAi, Rome 21.
Screening for fetal Down’s Syndrome – Improving efficacy and efficiency.
NON – INVASIVE PRENATAL TESTING
Prenatal diagnosis Dr Neda Bogari.
Trait and Sex Selection: The Arrival of Non-Invasive Prenatal Genetic Testing Jaime King, JD, PhD University of California, Hastings College of the Law.
Prenatal Genetic Testing for Chromosomal Anomalies By: Linda DeFranco.
Enhanced Prenatal Screening Program
Biochemical tests and ‘marker chemicals’
IN THE NAME OF GOD. CRITICALLY APPRAISED TOPIC If there is a Non-invasive prenatal testing for aneuploidies with low FPR at first trimester? If we can.
Pregnancy & Newborn Screening Developments
Ultrasound imaging.
Photo: courtesy Travel Alberta.  The provision of information for individuals  Women have the right to access information about the health of their.
TEMPLATE DESIGN © Retrospective Analysis of Amniocentesis in UKMMC ZulidaR, MAJamil Universiti Putra Malaysia, UPM Serdang,
First Trimester Screening
Multiple perspectives and mixed messages: narratives of evaluation of prenatal genetic screening Reproductive Heatlh Group Warwick November 2005.
Multiple perspectives and mixed messages: narratives of evaluation of prenatal genetic screening HTA, Rome June 2005.
Ahmad Teebi, M.D. Professor of Pediatrics and Genetic Medicine
Pregnancy Screening Pathway
The State of Ohio Universal Prenatal Booking David S. McKenna, MD, RDMS Maternal-Fetal Medicine Miami Valley Hospital, Dayton OH.
9/7/2015Mahia Samaha Alkony1 Genetics By: Mrs. Mahdiah Samaha Alkony.
Module One: Introduction to the California Prenatal Screening Program
National Women’s Screening for Aneuploidy Dr Emma Parry CMFM Clinical Director Maternal-Fetal Medicine National Women’s Health.
In the name of god First Trimester Screening Dr.M.Moradi.
Pregnancy diagnosis, Prenatal care & Genetic counseling Wei Jiang, M.D. Attending of Ob & Gyn Ob & Gyn Hospital, Fudan University 419 Fangxie Road, Shanghai.
Prenatal Diagnosis of Congenital Malformations for Undergraduates
VI. Hrvatski kongres o ginekološkoj endokrinologiji, humanoj reprodukciji i menopavzi s međunarodnim sudjelovanjem , Brijuni DARIJA STRAH.
Vajiheh Marsoosi, M.D Associate Professor of TUMS Shariati Hospital.
The New Prenatal Screening Tests Langley Memorial Hospital Grand Rounds November 8, 2007 Ken Seethram, MD, FRCSC, FACOG Obstetrics and Gynecology, Burnaby.
The Role of Prenatal screening as part of Routine Obstetric Care
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the ability.
NHS Fetal Anomaly Screening Programme Marie Coughlin Screening Lead January 25 th 2010.
Antenatal (Prenatal) Screening Higher Human Biology Unit 2 – Human Physiology.
HIGHER HUMAN BIOLOGY Unit 2 Physiology and Health 1. Ante-natal Screening.
Erika Castro, PGY 3 Cook County-Loyola-Provident Family Medicine Residency 2/27/2014 PRENATAL SCREENING AND DIAGNOSIS COUNSELING
BACKGROUND Despite the well established link between fetal macrosomia and maternal diabetes, it is estimated that 80% of macrosomic babies are born to.
Genetic Testing in Pregnancy Lisbeth M. Lazaron, MD March 2013.
UOG Journal Club: January 2016 Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results.
Genetic Counseling and Prenatal Diagnosis Dr. Hassan Nasrat FRCS & FRCOG Professor Dept. Obstetrics & Gynecology King Abdulaziz University Hospital.
UOG Journal Club: March 2016 Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of.
UOG Journal Club: July 2013 Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies M. M. Gil, M. S. Quezada, B. Bregant,
Prenatal Screening and Diagnosis. What is Prenatal Diagnosis?  In-utero detection of fetal anomalies General population risk is 3-5% for any birth defect.
a systematic review and meta-analysis
UOG Journal Club: June 2017 Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation: comparison with NICE.
UOG Journal Club: January 2016
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the.
UOG Journal Club: March 2016
Antenatal Screening Rebecca Sykes.
Ziya Kalem,MD Gurgan Clinic IVF and Women Health Center
d. Ante- natal and post-natal screening
Jeffrey A. Kuller, MD; Sean C. Blackwell, MD
Genetic Testing Result Means. Before Genetic Testing  The result of genetic testing can be life changing.  It is important for patients and their families.
Pregnancy diagnosis, Prenatal care & Genetic counseling
Why are Asian women less likely to make informed and autonomous choice in prenatal screening? Japanese Women’s Experiences of Prenatal Screening for Detecting.
guidance on antenatal screening
Following screening, genetic testing can occur during pregnancy for Down syndrome, Trisomy 18, and other conditions. Two major types of genetic testing.
NON – INVASIVE PRENATAL TESTING
Most provincial and territorial health insurance programs cover prenatal blood screening for chromosomal anomalies (Down syndrome and Trisomy 18) and neural.
Nuchal translucency screening uses ultrasound to screen for Down syndrome, other conditions caused by an extra chromosome (trisomy 13 and 18), and congenital.
WHAT IS AVAILABLE WHEN? Non-invasive prenatal testing
Presentation transcript:

SOCIAL IMPLICATIONS OF GENETIC PRENATAL SCREENING IN PREGNANCY

Innovative Health Technologies Programme Projects funded in the area of genetics Pregnancy & Childbirth ä Definitions of Genetic Knowledge and Pre- Implantation Genetic Diagnosis ä Social & Ethnic Differences in attitudes & consent to prenatal testing ä The Technological Management of Childbirth - risk, empowerment & professional accountability ä Social Implications of One Stop First Trimester Prenatal Screening

Innovative Health Technologies Programme Projects funded in the area of genetics Other types of genetic screening ä The construction of risk estimates in a cancer genetics clinic ä Genetic screening for Susceptibility to Disease: The Case of Haemochromatosis

Projects On The Social Implications Of Genetics

SETTINGSClinicsHospitalsHomes

ISSUES COMMON TO MOST OF THE PROJECTS IN GENETICS ä The management and meaning of risk ä The impact of technologies in the workplace ä The impact of technologies on women, patients and their families ä The process of explanation and decision making

Researching Innovative Technologies is involving ä Development of innovative social science methods ä Crossing disciplinary and professional domains ä Dialogue on the social negotiation of genetic information and choice

Social Implications of One Stop First Trimester Prenatal Screening ä Professor GA Lewando- Hundt ä Professor Jane Sandall ä Professor Bob Heyman ä Dr Kevin Spencer ä Dr Clare Williams ä Rachel Grellier ä Warwick University ä King’s College, London ä City University, London ä Barking, Havering & Redbridge NHS Trust ä King’s College, London ä Warwick University

Prenatal Screening for Trisomy 21 Conventional Second Trimester (15-18 weeks) Approach ä Maternal blood test to measure a combination of 2 to 4 biochemical markers in a batched process in a centralised lab. ä Patient specific risk reported to ANC 2 to 4 days later. 5-6% of women identified “At Risk” ä “At Risk” women brought back for counselling re. Invasive Diagnostic Test

Prenatal Screening for Trisomy 21 Conventional Second Trimester (15-18 weeks) Approach ä Amniocentesis performed - fluid sent away to Regional Reference Lab. ä 2 to 3 weeks later diagnosis reported to ANC ä Patient returns for further counselling. ä TOP if considered appropriate around 21 weeks -some 32 days after initial screen. ä DR 70% FPR 5% No of invasive procedures per case detected is 55

OSCAR - A One Stop Clinic for Assessment of Risk for fetal anomalies. Kevin Spencer Endocrine Unit,Clinical Biochemistry Dept., Harold Wood Hospital, Romford, U.K.

Developments & Innovations Leading to OSCAR ä Ultrasound markers of chromosomal anomalies - fetal nuchal translucency thickness at weeks.

Increased fetal nuchal translucency thickness in a case of T21 Head Upper limbs Lower limbs NT

Developments & Innovations Leading to OSCAR ä Ultrasound markers of chromosomal anomalies - fetal nuchal translucency thickness at weeks.  Biochemical markers of chromosomal anomalies - free  hCG & PAPP-A at weeks.

Developments & Innovations Leading to OSCAR ä Ultrasound markers of chromosomal anomalies - fetal nuchal translucency thickness at weeks.  Biochemical markers of chromosomal anomalies - free  hCG & PAPP-A at weeks. ä Development of new rapid assay technology for biochemical marker measurement.

Kryptor Analyser Nobel Prize winning chemistry ä Small bench top analyser - clinic based ä Rapid assay times (19 mins) ä Kinetic reading - leading to automatic rediluting of high samples within 4 minutes ä Precise - cv less than 3% between day ä Continuous sample access - stat capability ä Small sample (<50ul) and reagent (<150ul) volumes. ä User friendly

Developments & Innovations Leading to OSCAR ä Ultrasound markers of chromosomal anomalies - fetal nuchal translucency thickness at weeks.  Biochemical markers of chromosomal anomalies - free  hCG & PAPP-A at weeks. ä Development of new rapid assay technology for biochemical marker measurement. ä Predicted DR 90% for 5% FPR. No of invasive procedures per case detected is 30

OSCAR clinic flow Patient booked for a 13:00 appointment (15 minute intervals)

Professional Interactions OSCAR Midwives Support Workers Obstetricians Technologists Ultrasonographers

Prospective First Trimester Screening June ‘98 - May ‘99 ä Total births4397 ä Women offered screening4190 (95.3%) ä Women accepting4088 (97.6%) ä 88% of T21 cases detected & 95% of all Chromosomal anomalies over past 2 years Spencer et al (2000) BJO&G 107;1271

Screening options - time scales ä 2nd trimester biochemistry - results usually within 3 days, amniocentesis within 3 days, diagnostic test results 3- 4 weeks after screening. ä 1st trimester NT&Biochem - results within 1 hour, CVS within 2 days, diagnostic test results 7-10 days after screening.

Aim of study ä To explore and compare the risks and benefits of innovative and established models of genetic prenatal screening as defined, perceived and communicated by health professionals and pregnant women.

Research questions ä Do innovative prenatal screening methods for foetal anomalies impact differently on the social management of screening and testing ? ä What are the experiences of women of innovative and established genetic prenatal screening systems ? ä Do inter-professional roles, and relationships between professionals and clients, change ?

Research questions ä How do innovative and established prenatal screening systems affect women’s conceptions of self, and of the foetus ? ä How do they impact on the management of reproductive risk in the clinic and the home ?

Theoretical background ä Social context of reproduction and reproductive technologies ä Contrasting understandings of risk ä Sociology of the professional and expert groups

Methods ä Research will take place at two sites: one offering the innovative one stop approach, the other offers conventional second trimester prenatal screening. ä Multi-method approach ä Perspectives on clinic consultations at critical screening junctures with a sub-sample from health professionals and women.

Methods ä Focus groups with health professionals ä Survey of representative sample of women examining expectations about, and reflections on different screening processes.

Contribution to the IHT programme The study will offer insights into:- ä Participants’ broader response to the new emerging technology of prenatal screening; their views about its routinisation and notions of genetic responsibility. ä The impact of new screening technologies on, and the social management of pregnancy and interprofessional relationships, between obstetrics, midwifery and biomedicine.

Contribution to the IHT programme The study will offer insights into:- ä The social context of pregnancy, and perspectives on identity and the body. ä Understanding of complex probabilistic information and of risk.